A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

Stopped early · Phase 1/Phase 2

Conditions studied: Type 1 Diabetes

In brief

VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.

Key facts

Study ID

NCT04678557

Run by

ViaCyte

People needed

31

Starts

2019-06-25

Expected to finish

2021-11-19

Last updated by the study team

2023-10-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and non-pregnant women
• Diagnosis of T1DM for a minimum of 3 years.
• Stable, optimized diabetic regimen
• Acceptable candidate for implant and explant procedures.
• Willing and able to comply with protocol requirements.
• Meet insulin dosing requirements per protocol

You may not qualify if…

• Advanced complications associated with diabetes

Where it is running

• AMCR Institute — Escondido, California, United States
• Diablo Clinical Research — Walnut Creek, California, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Texas Diabetes & Endocrinology — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.